Soliris - a new monoclonal antibody

Alexion has launched Soliris (eculizumab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

PHARMACOLOGY
Eculizumab is a recombinant humanised monoclonal antibody. It prevents complement-mediated lysis of PNH red blood cells which are abnormally sensitive to destruction.

Eculizumab achieves this by specifically binding to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.

This results in decreased haemolysis, decreased transfusions and a reduction in occurrence of thrombosis in PNH patients.

 

Further information: Alexion 01483 246641

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more